entertainment -WSS

entertainment

author：knowledge 2025-09-30 00:46:09 - browse：5976

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： What AstraZeneca

leisure time

explore

WSS

What AstraZeneca

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

'Vaccine

Elisabeth Bik tackles the widespread issue of research misconduct

Color Health wants to make cancer screenings convenient

What AstraZeneca

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Many immigrants are left out of maternal health programs

Drug repurposing or repositioning? The language matters

Redefining sustainability for the pharmaceutical industry

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

What does generative AI mean for health care? We asked experts

Doctor of U.S. President Joe Biden says he is fit for duty

The cancer drug shortage isn’t new — and neither are the solutions

Doctors in states that ban abortion can still help patients

leisure time

Redefining sustainability for the pharmaceutical industry

Medicare isn't yet testing food as medicine

Elisabeth Bik tackles the widespread issue of research misconduct

Poland's lawmakers approve a divisive law on Russian influence

CDC advisory group OKs chikungunya vaccine

Pfizer is about to make a big push in cancer. Will investors listen?

leisure time

explore

hotspot

explore